Results 141 to 150 of about 12,907,435 (362)
THE LOSS OF PHENOTYPIC TRAITS BY DIFFERENTIATED CELLS [PDF]
, 1969 Samuel Chacko +3 more
openalex +1 more source
Landscape of BRAF transcript variants in human cancer
Molecular Oncology, EarlyView.We investigate the annotation of BRAF variants, focusing on protein‐coding BRAF‐220 (formerly BRAF‐reference) and BRAF‐204 (BRAF‐X1). The IsoWorm pipeline allows us to quantify these variants in human cancer, starting from RNA‐sequencing data. BRAF‐204 is more abundant than BRAF‐220 and impacts patient survival.
Maurizio S. Podda +5 more
wiley +1 more source
Role of PD-1 during effector CD8 T cell differentiation
Proceedings of the National Academy of Sciences of the United States of America, 2018 Eunseon Ahn +9 more
semanticscholar +1 more source
Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer
Molecular Oncology, EarlyView.Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...
Greta Gudoityte +10 more
wiley +1 more source
GENE EXPRESSION IN DIFFERENTIATED CELLS [PDF]
, 1963 Eric H. Davidson +2 more
openalex +1 more source
Epigenetic control of CD8+ T cell differentiation
Nature reviews. Immunology, 2018 A. Henning, R. Roychoudhuri, N. Restifo
semanticscholar +1 more source
Molecular Oncology, EarlyView.The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song +11 more
wiley +1 more source
DIFFERENTIATION OF BLOOD CELLS WITH PHASE CONTRAST MICROSCOPE
, 1957 Junta Kamura, Zensuke Ota
openalex +2 more sources
Molecular Oncology, EarlyView.In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton +17 more
wiley +1 more source
Changes in microsomal components accompanying cell differentiation of pea-seedling roots [PDF]
, 1961 UE LOENING
openalex +1 more source